The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.
Opthea Limited has announced that OPT-302, the Company’s VEGF-C/D “trap” inhibitor will be highlighted during an oral presentation at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting in Seattle, Washington.
During the scientific sessions at the ASRS conference, Dante Pieramici, MD, Director of the California Retina Research Foundation, Partner at California Retina Consultants, will present new pharmacokinetics and pooled safety data on OPT-302 as follows:
Oral presentation Title: Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases
Session: Pharmacology Symposium
Date and time: July 31, 2023, 4:10-4:14 pm PST
In addition, Opthea will also be featured in a wet age-related macular degeneration (wet AMD) Key Opinion Leader (KOL) virtual fireside chat discussing market trends and new treatments in wet AMD entitled “Live From ASRS” hosted by Hartaj Singh, Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. Two world renowned retina disease experts, Charles Wycoff MD, PhD, the Director of Research at Retina Consultants of Texas, Chairman of Research, Retina Consultants of America, and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital, and Dante Pieramici, MD, will serve as panelists alongside Megan Baldwin, PhD, Opthea’s Chief Executive Officer.
The Oppenheimer & Co sponsored “Live from ASRS” wet AMD forum takes place on August 1, 2023 at 8 am PST. The session will be accessible virtually. Register at https://opco.zoom.us/webinar/register/WN_9HTx70FDRa6yIeUcEODn6w
Baldwin commented on these news in the press release, saying, “At a time when most new wet AMD treatment candidates are largely focused on extending dosing treatment intervals in wet AMD, we look forward to sharing new data on the pharmacokinetics of OPT-302 to improve upon vision outcomes for patients above what is currently achieved with standard-of-care anti-VEGF-A monotherapy. Opthea is also appreciative of Oppenheimer for featuring the current global Phase 3 clinical program of OPT-302 and its potential value as a novel wet AMD treatment, as part of the hosted 'Live from ASRS' KOL forum.”